Abstract
Previous studies have reported an association between the ACE-I/D-polymorphism and
coronary heart disease (CHD) in patients with diabetes mellitus. However, ACE inhibitor
treatment, which could have compensated for negative effects of the D/D form of the
ACE gene polymorphism, was not considered in the studies. We investigated the influence
of the ACE-I/D polymorphism and the ACE inhibitor treatment in patients with diabetes
mellitus on the occurrence of CHD by multiple-regression analysis. Distribution of
the ACE gene I/D-polymorphism was investigated in 691 patients with diabetes mellitus
prospectively characterised for the presence/absence of coronary heart disease. The
distribution of DD; ID; II genotypes was 105 vs. 202 vs. 102 (25.7 % vs. 49.4 % vs.
24.9) in the CHD+ group and 55 vs. 160 vs. 67 (19.5 % vs. 56.7 % vs. 23.8 %) in the CHD- group, respectively (p = 0.1). A multiple logistic regression analysis introducing
the typical risk factors for CHD (age, gender, smoking, BMI > 26 kg/m2 , LDL elevation, HbA1c > 7 %) could not identify the ACE gene I/D-polymorphism as
an independent risk factor for CHD (p = 0.87). Our data therefore suggest that the
ACE gene I/D polymorphism is not associated with the occurrence of diabetic macroangiopathy
in patients with or without treatment of ACE inhibitors.
Key words
Diabetes - Genetics - Complications of Diabetes
References
1
Seaquist E R, Goetz F C, Rich S, Barbosa J.
Familial clustering of diabetic kidney disease: Evidence for genetic susceptibility
to diabetic nephropathy.
N Engl J Med.
1989;
320
1161-1165
2
Pettitt D J, Saad M F, Bennett P H, Nelson R G, Knowler W C.
Familial predisposition to renal disease in two generations of Pima indians with type
II (non-insulin dependent) diabetes mellitus.
Diabetologia.
1990;
33
438-443
3
Ballard D J, Humphrey L L, Melton 3rd L J.
Epidemiology of persistent proteinuria in typ II diabetes mellitus. Population based
study in Rochester Minnesota.
Diabetes.
1998;
37
405-412
4
Rossing P, Rossing K, Jacobsen P.
Unchanged incidence of diabetic nephropathy in IDDM patients.
Diabetes.
1995;
44
739-743
5
Caprio S, Wong S, Alberti K GMM.
Cardiovascular complications of diabetes.
Diabetologia.
1997;
40
B78-B82
6
Panzram G.
Mortality and survival in Type 2 (non insulin dependent) diabetes mellitus.
Diabetologia.
1987;
30
123-131
7
Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hörmann A, Holle R.
Predictors of 10-year macrovascular and overall mortality in patients with NIDDM:
the Munich General Practitioner Project.
Diabetologia.
1996;
39
1540-1545
8
Francis G S.
ACE inhibition in cardiovascular disease.
N Engl J Med.
2000;
342
201-202
9
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dageneais G.
Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
N Engl J Med.
2000;
342
145-153
10
Pahor M, Psaty B M, Alderman M H, Applegate W B, Williamson J D, Furberg C D.
Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients
with type 2 diabetes.
Diab Care.
2000;
23
888-892
11
Szucs T, Schneeweiss A.
Cilazapril: an overview of its efficacy and safety in hypertension.
Cardiology.
1992;
80
34-41
12
Nazzaro P, Manzari M, Merlo M, Triggiani R, Scarano A M, Lasciarrea A, Marella N,
Pirelli A.
Stress reactivity in responder and non-responder hypertensives treated with verapamil
and enalapril.
Riv Eur Sci Med Pharmacol.
1995;
17
105-113
13
Valles P M, Matas S M, Bronsoms A J, Mate B G, Torguet E P, Mauri N JM.
Quinapril ACE-inhibition effects on adrenergic parameters in moderate essential hypertension.
Kidney Int Suppl.
1996;
55
S104-106
14
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F.
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting
for half the variance of serum enzyme levels.
J Clin Invest.
1990;
86
1343-1346
15
Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F.
Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin
I-converting enzyme (ACE) gene controls plasma ACE levels.
Am J Hum Genet.
1992;
51
197-205
16
Ruiz J, Blanche H, Cohen N, Velho G, Cambien F, Cohen D, Passa P, Froguel P.
Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly
associated with coronary heart disease in non-insulin-dependent diabetes mellitus.
Proc Natl Acad Sci.
1994;
91
3662-3665
17
Cambien F O, Poirier O, Lecerf L, Evans A, Cambou J-P, Arveiler D, Luc G, Bard J-M,
Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas F, Soubrier F.
Deletion polymorphism in the gene for angiotensin converting enzyme is a potent risk
factor for myocardial infarction.
Nature.
1992;
359
641-644
18
Fujisawa T, Ikegami H, Shen G Q, Yamato E, Takekawa K, Nagakawa Y, Hamada Y, Ueda H,
Rakugi H, Higaki J.
Angiotensin-I-converting enzyme gene polymorphism is associated with myocardial infarction,
but not with retinopathy or nephropathy, in NIDDM.
Diabetes Care.
1995;
18
983-985
19
Lindpaintner L, Pfeffer M A, Kreutz R, Stampfer M J, Grodstein F, LaMotte F, Buring J,
Hennekens C H.
A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and
the risk of ischemic heart disease.
N Engl J Med.
1995;
332
706-711
20
Ribichini F, Steffenino G, Dellavalle A, Matullo G, Colajanni E, Camilla T, Vado A,
Benetton G, Uslenghi E, Piazza A.
Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme.
A major risk factor and a marker of risk for coronary stent restenosis.
Circulation.
1998;
97
147-154
21
Ruiz J, Blanche H, James R W, Blatter-Garin M C, Vaisse C, Charpentier G, Cohen N,
Morabia A, Passa P, Froguel P.
Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes.
Lancet.
1995;
346
869-872
22
Antikainen M, Murtomäki S, Syvänne M, Pahlmann R, Tahvanainen E, Jauhiainen M, Frick M H,
Ehnaholm C.
The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated
with the risk of coronary artery disease in Finns.
J Clin Invest.
1996;
98
883-885
23
Odawara M, Tachi Y, Yamashita K.
Paraoxonase polymorphism (Gln192Arg) is associated with coronary heart disease in
Japanese non insulin dependent diabetes mellitus.
J Clin Endocrinol Metab.
1997;
82
2257-2260
24
Serrato M, Marian A J.
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary
artery disease.
J Clin Invest.
1995;
96
3005-3008
25
Kunkel G R, Graham J B, Fowlkes D M, Lord S T.
Rsa I Polymorphism in von Willebrand factor (vWF) at codon 789.
Nucl Acid Res.
1990;
18
4961
26
Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F.
Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism
of expression in T-lymphocytes.
Biochem J.
1993;
290
33-34
27
Keavney B D, Dudley C R, Stratton I M, Holman R R, Matthews D R, Ratcliffe P J, Turner R C.
UK prospective diabetes study (UKPDS) 14: association of angiotensin-converting enzyme
insertion/deletion polymorphism with myocardial infarction in NIDDM.
Diabetologia.
1995;
38
948-952
28
The CONSENSUS Trial Study Group .
Effects of enalapril on mortality in severe congestive heart failure. Results of the
cooperative heart north Scandinavian enalapril survival study (CONSENSUS).
N Engl J Med.
1987;
316
1429-1435
29
The SOLVD investigators.
Effect of enalapril on survival in patients with reduced left ventricular ejection
fractions and congestive heart failure.
N Engl J Med.
1991;
325
293-302
30
Montgomery H, Clarkson P, Barnard M, Bell J, Brynes A, Dollery C, Hajnal J, Hemingway H,
Mercer D, Jarman P, Marshall R, Prasad K, Rayson M, Saeed N, Talmud P, Thomas L, Jubb M,
World M, Humphries S.
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to
physical training.
Lancet.
1999;
353
541-545
31
Williams A G, Rayson M P, Jubb M, World M, Woods D R, Hayward M, Martin J, Humphries S E,
Montgomery H E.
The ACE gene and muscle performance.
Nature.
2000;
403
614
32
Keavney B, McKenzie C, Parish S, Palmer A, Clark S, Youngman L, Delephine M, Lathrop M,
Peto R, Colins R for the International Studies of Infarct Suvival (ISIS) Collaborators.
Large-scale test of hypothesised associations between the angiotensin-converting-enzyme
insertion/deletion polymorphism and myocardial infarction in about 5000 cases and
6000 controls.
Lancet.
2000;
355
434-442
33
Friedl W, Krempler F, Paulweber B, Pichler M, Sandhofer F.
A deletion polymorphism in the angiotensin converting enzyme gene is not associated
with coronary heart disease in an Austrian population.
Atherosclerosis.
1995;
112
137-143
34
Pfohl M, Koch M, Prescod S, Haase K K, Häring H U, Karsch K R.
Angiotensin-I-converting enzyme gene polymorphism, coronary artery disease and myocardial
infarction. An angiographically controlled study.
Eur Heart J.
1999;
20
1318-1325
35
Arca M, Pannitteri G, Campagna F, Candeloro A, Montali A, Cantini R, Seccareccia F,
Campa P P, Marino B, Ricci G.
Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis
and myocardial infarction in a sample of Italian patients.
Eur J Clin Invest.
1998;
28
485-490
36
Agerholm-Larsen B, Nordestgaard B G, Steffensen R, Sörensen T IA, Jensen G, Tybjaerg-Hansen A.
ACE gene polymorphism: ischemic heart disease and longevity in 10 150 individuals.
Circulation.
1997;
95
2358-2367
R. Paschke, M.D.
III. Medical Department · Leipzig University
Philipp-Rosenthal-Strasse 27 · 04103 Leipzig · Germany ·
Telefon: + 49 (341) 971 32 00
Fax: + 49 (341) 971 32 09 ·
eMail: Pasr@server3.medizin.uni-leipzig.de